Santa Monica, CA, United States
Santa Monica, CA, United States

Time filter

Source Type

Patent
Agensys Inc. and Seattle Genetics | Date: 2016-03-14

Antibody drug conjugates (ADCs) that bind to 191P4D12 protein and variants thereof are described herein. 191P4D12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADCs of the invention provide a therapeutic composition for the treatment of cancer.


Patent
Agensys Inc. and Seattle Genetics | Date: 2015-02-27

Antibody drug conjugates (ADCs) that bind to 158P1D7 protein and variants thereof are described herein. 158P1D7 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in glioblastoma, lung cancer, bladder cancer, and breast cancer. Consequently, the ADCs of the invention provide a therapeutic composition for the treatment of cancer.


Patent
Agensys Inc. and Seattle Genetics | Date: 2015-07-13

Antibody drug conjugates (ADCs) that bind to 191P4D12 protein and variants thereof are described herein. 191P4D12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADCs of the invention provide a therapeutic composition for the treatment of cancer.


Patent
Agensys Inc. and Seattle Genetics | Date: 2016-03-30

Antibody drug conjugates (ADCs) that bind to 158P1D7 protein and variants thereof are described herein. 158P1D7 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in glioblastoma, lung cancer, bladder cancer, and breast cancer. Consequently, the ADCs of the invention provide a therapeutic composition for the treatment of cancer.


Patent
The Regents Of The University Of California and Agensys Inc. | Date: 2016-06-13

The invention provides a novel prostate cell-surface antigen, designated Prostate Stem Cell Antigen (PSCA), which is widely over-expressed across all stages of prostate cancer, including high grade prostatic intraepithelial neoplasia (PIN), androgen-dependent and androgen-independent prostate tumors.


Antibodies and molecules derived therefrom that bind to novel STEAP-1 protein, and variants thereof, are described wherein STEAP-1 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, STEAP-1 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The STEAP-1 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with STEAP-1 can be used in active or passive immunization


The invention described herein relates to novel nucleic acid sequences and their encoded proteins, referred to as 158P1D7 and variants thereof, and to diagnostic and therapeutic methods and compositions useful in the management of various cancers that express 158P1D7 and variants thereof.


Patent
Agensys Inc. | Date: 2014-07-30

Antibody drug conjugates (ADCs) that bind to CD37 protein and variants thereof are described herein. CD37 exhibits a distinct and limited expression pattern in normal adult tissue(s), and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADCs of the invention in some embodiments provide a therapeutic composition for the treatment of cancer.


Antibody drug conjugates (ADCs) that bind to 161P2F10B protein are described herein. 161P2F10B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADCs of the invention provide a therapeutic composition for the treatment of cancer.


Patent
Agensys Inc. | Date: 2016-03-09

Antibody drug conjugates (ADCs) that bind to FLT3 protein and variants thereof are described herein. FLT3 exhibits a distinct and limited expression pattern in normal adult tissue(s), and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADCs of the invention provide a therapeutic composition for the treatment of cancer.

Loading Agensys Inc. collaborators
Loading Agensys Inc. collaborators